Mahboubeh Rahmani1, Brooke M Fortin2, Nancy Berliner2, Nicolas Issa3, Donna Neuberg4, Richard M Kaufman5, John M Gansner2. 1. Division of Hematopathology, Dalhousie University, Halifax, Nova Scotia, Canada. 2. Hematology Division, Brigham and Women's Hospital, Boston, Massachusetts. 3. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts. 4. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 5. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: We recently discovered that 30% of current frequent apheresis platelet donors in a study at our donor center had CD4+ counts below 200 cells/μL. How long CD4+ lymphopenia persists after ceasing plateletpheresis is unknown. Whether there are infectious or other complications in former frequent donors that could relate to CD4+ lymphopenia is also unknown. STUDY DESIGN AND METHODS: We mailed a letter to former frequent apheresis platelet donors who had not donated platelets for at least 12 months. Frequent donation was defined as 20 to 24 plateletpheresis sessions in at least one 365-day period starting in 2011. Donors who expressed interest in the study were contacted to schedule a study visit. Participants in the study provided a blood sample and completed a health questionnaire that included questions about opportunistic infections and malignancies. RESULTS: Of 50 potential study candidates who were mailed a letter, 15 participated in the study. There were 2 participants with CD4+ counts below 200 cells/μL, one of whom had prior counts that documented a small improvement with cessation of plateletpheresis. Three participants had counts between 200 and 300 cells/μL. No study participant had a history of an opportunistic infection or a malignancy associated with immune dysregulation. CONCLUSION: We detected CD4+ lymphopenia in former frequent apheresis platelet donors who had ceased platelet donation for more than 1 year. There was no evidence that the CD4+ lymphopenia predisposes to opportunistic infections or to malignancies associated with immune dysregulation.
BACKGROUND: We recently discovered that 30% of current frequent apheresis platelet donors in a study at our donor center had CD4+ counts below 200 cells/μL. How long CD4+ lymphopenia persists after ceasing plateletpheresis is unknown. Whether there are infectious or other complications in former frequent donors that could relate to CD4+ lymphopenia is also unknown. STUDY DESIGN AND METHODS: We mailed a letter to former frequent apheresis platelet donors who had not donated platelets for at least 12 months. Frequent donation was defined as 20 to 24 plateletpheresis sessions in at least one 365-day period starting in 2011. Donors who expressed interest in the study were contacted to schedule a study visit. Participants in the study provided a blood sample and completed a health questionnaire that included questions about opportunistic infections and malignancies. RESULTS: Of 50 potential study candidates who were mailed a letter, 15 participated in the study. There were 2 participants with CD4+ counts below 200 cells/μL, one of whom had prior counts that documented a small improvement with cessation of plateletpheresis. Three participants had counts between 200 and 300 cells/μL. No study participant had a history of an opportunistic infection or a malignancy associated with immune dysregulation. CONCLUSION: We detected CD4+ lymphopenia in former frequent apheresis platelet donors who had ceased platelet donation for more than 1 year. There was no evidence that the CD4+ lymphopenia predisposes to opportunistic infections or to malignancies associated with immune dysregulation.
Authors: John M Gansner; Mahboubeh Rahmani; A Helena Jonsson; Brooke M Fortin; Idayat Brimah; Martha Ellis; Robin Smeland-Wagman; Zhihan J Li; Jason M Schenkel; Michael B Brenner; Revital Yefidoff-Freedman; Steven R Sloan; Nancy Berliner; Nicolas C Issa; Lindsey R Baden; Dan L Longo; Duane R Wesemann; Donna Neuberg; Deepak A Rao; Richard M Kaufman Journal: Blood Date: 2018-11-14 Impact factor: 22.113
Authors: Y Matsui; S Martin-Alosco; E Doenges; L Christenson; H M Shapiro; E J Yunis; P L Page Journal: Transfusion Date: 1986 Sep-Oct Impact factor: 3.157
Authors: Dimitrios I Zonios; Judith Falloon; John E Bennett; Pamela A Shaw; Doreen Chaitt; Michael W Baseler; Joseph W Adelsberger; Julia A Metcalf; Michael A Polis; Stephen B Kovacs; Stephen J Kovacs; Joseph A Kovacs; Richard T Davey; H Clifford Lane; Henry Masur; Irini Sereti Journal: Blood Date: 2008-05-02 Impact factor: 22.113
Authors: Jingcheng Zhao; Erin Gabriel; Rut Norda; Petter Höglund; Lindsey Baden; Beatrice A Diedrich; Per Marits; Sara L Enoksson; John M Gansner; Richard Kaufman; Paul W Dickman; Gustaf Edgren Journal: Transfusion Date: 2020-11-13 Impact factor: 3.157